December 18, 2017 / 8:23 AM / 10 months ago

BRIEF-TaiwanJ Pharmaceuticals starts Phase 2 clinical study of new drug JKB-122 on treatment of NAFLD

Dec 18 (Reuters) - TaiwanJ Pharmaceuticals Co Ltd :

* Says it starts Phase 2 clinical study of new drug JKB-122 on treatment of NAFLD, non-alcoholic fatty liver disease

* Clinical trail expects to be finished in 2018 Q3

Source text in Chinese: goo.gl/uQxhRd

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below